

Title: Haematology Reference Ranges and Clinical Decision Values (RLUH
BGH and LWH)

Rev. No: 3

Examination	Reference Range		Units	Basis
Haematology				
Full Blood Count	Male	Female		Blood Cells: A Practical Guide (Barbara J Bain) 2 nd edition 1995
Haemoglobin	140-180	120-160	g/L	In House
Red Blood Cell Count	4.4-6.0	4.2-5.4	x10 ¹² /L	In House
Haematocrit/ Packed Cell Volume	0.38-0.51	0.34-0.47	L/L	In House
Mean Cell Volume	80-100	80-100	fL	In House
Mean Cell Haemoglobin	27-33	27-33	pg	In House
Mean Cell Haemoglobin Concentration	320-370	320-370	g/L	In House
Red Cell Distribution Width	11.5-15.7	11.5-15.7	%	In House
Platelets	140-450	140-450	x10 ⁹ /L	In House
Mean Platelet Volume	7.2	7.2	fL	In House
White Blood Cell Count	4.0-11.0	4.0-11.0	x10 ⁹ /L	In House
Neutrophils	1.9-8.0	1.9-8.0	x10 ⁹ /L	In House
Lymphocytes	0.9-4.5	0.9-4.5	x10 ⁹ /L	In House
Monocytes	0.16-1.0	0.16-1.0	x10 ⁹ /L	In House
Eosinophils	0.0-0.8	0.0-0.8	x10 ⁹ /L	In House
Basophils	0.0-0.2	0.0-0.2	x10 ⁹ /L	In House
Reticulocytes	0.2-2.0	0.2-2.0	%	In House
Nucleated Red Blood Cells	<0.3	<0.3	x10 ⁹ /L	In House
Erythrocyte Sedimentation Rate	2-10	2-19	mm/hr	In House
Coagulation				
INR	Target Range for Patient		Ratio	
PT	9.0-13.0		Seconds	In House
APTT	25.0-36.0		Seconds	In House
APTT Ratio	1.8-3.3		Ratio	In House
Fibrinogen	1.50-3.50		g/L	In House
D-Dimer	<500		ng/mL	In House
HIT IgG	<1.0		U/mL	In House
LMWH (Prophylactic)	0.15-0.40		U/mL	In House
LMWH (Therapeutic)	0.40-0.80		U/mL	In House
Edoxaban	Target Range for Patient		ng/mL	
Rivaroxaban	Target Range for Patient		ng/mL	
Apixaban	Target Range for Patient		ng/mL	
FII	50-150		%	In House
FV	50-150		%	In House
FVII	50-150		%	In House

Title:	Haematology Reference Ranges and Clinical Decision Values (RLUH BGH and LWH)	Rev. No:	3
--------	--	----------	---

FVIII	40-145	%	In House
FVIII Chromogenic	40-145	%	In House
FVIII Inhibitor	<0.4	BU	In House
FIX Inhibitor	<0.4	BU	In House
FIX	50-150	%	In House
FXI	50-150	%	In House
FXII	50-150	%	In House
FXIII Antigen	75-155	%	In House
vW Activity	50-150	%	In House
vW Antigen	50-150	%	In House
vW RCO	50-150	%	In House
vW CBA	45-150	%	In House
AT Activity	80-125	%	In House
AT Antigen	85-135	%	In House
Protein C Activity	65-125	%	In House
Protein C Amidolytic	65-155	%	In House
Protein C Antigen	65-165	%	In House
Free Protein S (male)	75-145	%	In House
Free Protein S (female)	55-125	%	In House
Protein S Total	70-160	%	In House
APCV Ratio	2.61-3.32	Ratio	In House
DVVT	<1.20	Ratio	In House
DVVC	<1.20	Ratio	In House
DVVR	<1.20	Ratio	In House
Anticardiolipin IgG	<20	U/mL	In House
Anticardiolipin IgM	<20	U/mL	In House
Anti-β2 Glycoprotein IgG	<20	U/mL	In House
Anti-β2 Glycoprotein IgM	<20	U/mL	In House
ADAMTS13 Activity	40-130	%	In House
ADAMTS13 Activity (AcuStar)	60-130	%	In House
ADAMTS13 Inhibitor	<15	U/mL	In House

In House

Established and verified ranges in-house after completing a study of local patients; these were verified against manufacturers or other literature or clinical evaluation.

Doc. No:	BS-HAEM-INFO-11	Approved by:	L.Saminaden
Author:	A.Lawrenson/A.Cain	Page 2 of 2	Last printed 19/04/2023 09:29